Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.

Fabrizio VernieriNicoletta BrunelliSimona GuerzoniLuigi Francesco IannoneCarlo BaraldiRenata RaoFrancesca Schiano di ColaRaffaele OrnelloSabina CevoliCarlo LovatiMaria AlbaneseArmando PerrottaIlaria CettaSergio Soeren RossiValentina TarantaMassimo FilippiPierangelo GeppettiSimona SaccoClaudia Altamura

Published in: Journal of neurology (2023)

Anti-CGRP/CGRPr mAbs are effective in the second as in the first year. The use of anti-CGRP or CGRPr mAbs influenced the second-year baseline MMDs, but their effectiveness did not differ during the two treatment years.

Keyphrases

end stage renal disease
ejection fraction
randomized controlled trial
newly diagnosed
systematic review
prognostic factors
cross sectional
double blind